PDCD1 and melanoma: Furthermore, in melanoma patients that progressed after initial response to anti-PD-1 monotherapy or anti-PD-1 plus ipilimumab, the density of VISTA+lymphocytes was significantly increased (p = 0.009) compared to matched pre-treatment levels, arguing for an adaptive resistance mechanism [123].